2 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Salivary Gland Carcinomas: new trials by email Literature Review of Salivary Gland Carcinomas trials Research Report on Salivary Gland Carcinomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study MRG 003, Pucotenlimab - Salivary Gland Carcinomas | Phase 2 | Recruiting | Ji Dongmei | 90 | 2026-03-19 | 2026-04-01 |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) - Head and Neck Carcinoma, Adenoid Cystic Carcinoma | Phase 1 / Phase 2 | Recruiting | VM Oncology, LLC | 242 | 2018-06-08 | 2026-11-04 |
Carcinoma, Adenoid Cystic (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Laryngeal Diseases (1) · Lung Neoplasms (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Salivary Gland Neoplasms (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Tracheal Diseases (1)
Adenocarcinoma (1) · Adenoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Esophageal Diseases (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Lung Diseases (1) · Mouth Diseases (1)
Combined Modality Therapy (1) · Tablets (1) · pembrolizumab (1)
Ji Dongmei (1) · VM Oncology, LLC (1)
China (1) · Puerto Rico (1) · United States (1)